Stocktoria
PMGC Holdings Inc. ELAB
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2023-11-21
PMGC Holdings Inc. financials (annual)
Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $590,084 | — | $1.7M | $766,277 |
| Gross profit | $185,314 | — | $1.1M | $447,309 |
| R&D expense | $147,010 | $104,654 | $7,410 | $228,747 |
| Interest expense | — | — | $19,525 | $2,629 |
| Income tax | $30,972 | — | — | — |
| Net income | -$7.7M | -$6.2M | -$4.3M | -$1.8M |
| EPS (diluted) | — | — | $-0.40 | $-0.19 |
| Operating cash flow | -$5.9M | -$5.5M | -$4.6M | -$1.6M |
| Free cash flow | -$6.4M | -$5.5M | -$4.6M | — |
| Cash & equivalents | — | $4.0M | $3.3M | — |
| Inventory | $95,098 | — | $495,667 | $230,145 |
| Total assets | $12.9M | $9.0M | $5.2M | $1.9M |
| Total liabilities | $5.0M | $2.3M | $1.4M | $760,873 |
| Shareholders' equity | $7.8M | $6.7M | $3.8M | $1.1M |
Growth · year-over-year · Revenue CAGR -12.2%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue growth | — | — | +123.5% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.